Last edition
News about "Leqembi IQLIK"
US FDA Approves Leqembi Iqlik Subcutaneous Injection for Early Alzheimer's Disease
The US Food and Drug Administration (FDA) has approved Leqembi Iqlik (lecanemab-irmb) as a once-weekly subcutaneous starting dose for early Alzheimer's Disease (AD), with a U.S. launch planned for August 2026.
Leqembi Iqlik | 14/07/2026 | By News Bureau
LEQEMBI IQLIK Subcutaneous Dose Gets US FDA Priority Review for Early Alzheimer's Disease
LEQEMBI IQLIK subcutaneous dose review by US Food and Drug Administration (FDA) extended after major sBLA amendment for early Alzheimer’s disease, with no approvability concerns raised.
LEQEMBI IQLIK | 11/05/2026 | By News Bureau | 148
FDA Approves Eisai and Biogen's At-Home Alzheimer's Injection Leqembi IQLIK
Leqembi IQLIK, delivering a 360 mg dose within 15 seconds, will be available from 6 October, 2025, at a list price of USD 19,500 annually for a pack of pre-filled autoinjectors.
Leqembi IQLIK | 30/08/2025 | By Dineshwori | 698
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy